An updated meta-analysis of fatal adverse events caused by bevacizumab therapy in cancer patients.

ABSTRACT:

Background

The risk of fatal adverse events (FAEs) due to bevacizumab-based chemotherapy has not been well described; we carried out an updated meta-analysis regarding this issue.

Methods

An electronic search of Medline, Embase and The Cochrane Central Register of Controlled Trials was conducted to investigate the effects of randomized controlled trials on bevacizumab treatment on cancer patients. Random or fixed-effect meta-analytical models were used to evaluate the risk ratio (RR) of FAEs due to the use of bevacizumab.

Results

Thirty-four trials were included. Allocation to bevacizumab therapy significantly increased the risk of FAEs; the RR was 1.29 (95% CI:1.05-1.57). This association varied significantly with tumor types (P=0.002) and chemotherapeutic agents (P=

SUBMITTER: Huang H 

PROVIDER: S-EPMC3943842 | biostudies-literature | 2014

REPOSITORIES: biostudies-literature